MUC1 Activated T Cells

Adoptive Transfer of MUC1 Activated T Cells for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

What's the purpose of the trial?

This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for expression of the MUC1 protein. 

Trial status

Accepting patients

Phase
Phase 1
Enrollment
18
Last Updated
2 months ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Cyclophosphamide
  • MUC1-activated T-cells

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

MUC1-Activated T-Cells

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.